Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

It Is Not Just the Royals Who Go Through Cancer.

2.

Have the Harms of Lung Cancer Screening Been Exaggerated?

3.

Cancer diagnosis does not spur improvements to survivors' diets or eating habits

4.

Novel Agent for Chronic GVHD Wins FDA Approval

5.

Rising rates of head and neck cancers in England


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot